NCT01521377 - QTc Study GSK573719+GW642444 | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 19, 2011

Primary Completion Date

June 5, 2012

Study Completion Date

June 5, 2012

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Placebo Moxifloxacin

Single dose placebo oral tablet Moxifloxacin

DRUG

Moxifloxacin

Single oral dose tablet Moxifloxacin (400mg)

DRUG

GSK573719/Vilanterol 125/25mcg

Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily

DRUG

GSK573719

Single inhalation from GSK573719 500mcg DPI once daily

DRUG

GSK573719/Vilanterol 500/100mcg

Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily

DRUG

Placebo DPI

Single Inhalation from matching Placebo DPI once daily

Trial Locations (1)

GSK Investigational Site, London